Medicare AdvantageCoverageMedium impact
MA08.157b, Teplizumab-mzwv (Tzield)
Independence Blue Cross·Endocrinology, Family Medicine, Internal Medicine +1 more·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.157b for Teplizumab-mzwv (Tzield) has been reissued with updates. This is a recent pharmacy policy change that may affect coverage, prior authorization, or billing requirements for this specialty diabetes medication.
Action Required
By May 28, 2025: Billing team should review the complete updated policy MA08.157b for Teplizumab-mzwv (Tzield) at the provided URL to identify specific changes to prior authorization requirements, coverage criteria, or billing procedures. Update billing system settings and staff training as needed based on the full policy content.